News Efficacy and Toxicity Seen With MIRV in Ovarian Cancer by Medscape • 2025/07/03 • 0 Comments New PICCOLO trial analyses showed that mirvetuximab soravtansine achieved 52% response rates and 27-month overall survival in patients with platinum-sensitive ovarian cancer. Medscape Medical News